Drug intelligence / Profile preview

HRS-2129

Development stage: Phase 3
Lead developer: Shandong Suncadia Medicine
Modality: Small Molecules
Administration: Oral

Overview

HRS-2129 is a novel small molecule analgesic under development for the treatment of acute and chronic pain, including postoperative pain. The drug is being developed by Shandong Suncadia Medicine (also referenced as Shandong Shengdi Pharmaceutical) and Shanghai Hengrui Medicine. As of mid-2025, it is in phase 1 clinical trials in China, with studies evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients undergoing orthopedic surgery. The precise mechanism of action has not been disclosed or defined publicly. There are currently no similar products approved for marketing domestically or abroad[1][2][5][7].

Targets

SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on HRS-2129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-2129.

Explore the full profile